Based on the knowledge of the melanoma biology, new therapeutic strategies including CTLA-4, PD-1 and PD-L1/2 blockers, aimed at restraining the molecular interplay between tumor cells and effector immune cells, have been developed and results from extended clinical trials describe a revolutionary improvement in the management of melanoma patients [13–18]. Here, CD274 is linked to neoplasm.